Dermovate 0,5 mg/g krēms Latvija - latvijski - Zāļu valsts aģentūra

dermovate 0,5 mg/g krēms

glaxosmithkline (ireland) limited, ireland - klobetazola propionāts - krēms - 0,5 mg/g

Dermovate 0,5 mg/g ziede Latvija - latvijski - Zāļu valsts aģentūra

dermovate 0,5 mg/g ziede

glaxosmithkline (ireland) limited, ireland - klobetazola propionāts - ziede - 0,5 mg/g

Dermovate 0,5 mg/g ziede Latvija - latvijski - Zāļu valsts aģentūra

dermovate 0,5 mg/g ziede

glaxosmithkline (ireland) limited, ireland - klobetazola propionāts - ziede - 0,5 mg/g

Dermovate 0,5 mg/g ziede Latvija - latvijski - Zāļu valsts aģentūra

dermovate 0,5 mg/g ziede

glaxo wellcome uk, united kingdom - klobetazola propionāts - ziede - 0,5 mg/g

Dermovate 0.5 mg/g krēms Latvija - latvijski - Zāļu valsts aģentūra

dermovate 0.5 mg/g krēms

glaxo wellcome uk, united kingdom - klobetazola propionāts - krēms - 0,5 mg/g

CLOBETASOL PROPIONATE shampoo Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

clobetasol propionate shampoo

actavis pharma, inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate 0.05 g in 100 ml - clobetasol propionate shampoo, 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older. treatment should be limited to 4 consecutive weeks. the total dosage should not exceed 50 g (50 ml or 1.75 fl. oz.) per week. patients should be instructed to use clobetasol propionate shampoo, 0.05%, for the minimum time period necessary to achieve the desired results [see dosage and administration (2)]. use in patients younger than 18 years of age is not recommended due to numerically high rates of hypothalamic-pituitary-adrenal (hpa) axis suppression [see warnings and precautions (5.1) and use in specific populations (8.4)]. clobetasol propionate shampoo, 0.05%, should not be used on the face, groin or axillae. avoid any contact of the drug product with the eyes and lips. in case of contact, rinse thoroughly with water all parts of the body that came in contact with the shampoo. none teratogenic effe

CLOBETASOL PROPIONATE shampoo Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

clobetasol propionate shampoo

sandoz inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate 0.05 g in 100 ml - clobetasol propionate shampoo, 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older. treatment should be limited to 4 consecutive weeks. the total dosage should not exceed 50 g (50 ml or 1.75 fl. oz.) per week. patients should be instructed to use clobetasol propionate shampoo, 0.05%, for the minimum time period necessary to achieve the desired results [see dosage and administration (2) ]. use in patients younger than 18 years of age is not recommended due to numerically high rates of hypothalamic-pituitary-adrenal (hpa) axis suppression [see warnings and precautions (5.1) and use in specific populations (8.4) ]. clobetasol propionate shampoo, 0.05%, should not be used on the face, groin or axillae. avoid any contact of the drug product with the eyes and lips. in case of contact, rinse thoroughly with water all parts of the body that came in contact with the shampoo. none terat

CLOBETASOL PROPIONATE cream Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

clobetasol propionate cream

ipg pharmaceuticals, inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate 0.5 mg in 1 g - clobetasol propionate cream is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.